FlotoReview
424B4 filings

ABVC BioPharma Files 424B4 Prospectus: What the Filing Shows

ABVC BioPharma filed a final 424B4 prospectus with the SEC on Nov. 13, 2026. Here is what the filing is, what is confirmed, and what to check in its pricing pages.

Nov 14, 20263 min read
3min read
1sources
3topics
Nov 14published

Key takeaways

  • ABVC BioPharma, Inc. filed a 424B4 prospectus with the U.S. Securities and Exchange Commission on Nov. 13, 2026, at 4:30 p.m. Eastern.
  • The document is about 968 KB, and its SEC accession number is 0001213900-26-119789.
  • A 424B4 is the final prospectus a company files after an offering is priced. It is where the actual terms are set out.
  • Price, share count, proceeds and underwriting terms are in the document itself. This article does not quote them.

What was filed

ABVC BioPharma, Inc. (SEC central index key 0001173313) submitted a 424B4 on Friday afternoon, Nov. 13, 2026. EDGAR logged the filing at 4:30 p.m. Eastern. The submission is roughly 968 KB, which is a full-length prospectus rather than a short supplement.

DetailFiling record
FilerABVC BioPharma, Inc.
Form type424B4
FiledNov. 13, 2026
Accession number0001213900-26-119789
Size968 KB

Why a 424B4 prospectus matters

Companies selling securities to the public file a registration statement first. Early versions carry blanks or ranges for price and size. After the deal is priced, the company files the final prospectus under Rule 424(b)(4). That filing replaces the estimates with the numbers investors actually paid.

For IPO pricing reviews, this is the document that counts. It fixes the offering price and the number of securities sold. It also states the underwriting arrangements, the planned use of proceeds, and the capitalization and dilution tables as they stand after the deal. Earlier drafts and press coverage are only previews.

A 424B4 does not by itself mean the offering is a first-time listing. Established public companies also use the form for follow-on sales. Readers should confirm from the cover page whether the transaction is an initial public offering or a later sale of securities.

What to check in the document

Readers working through the prospectus can start with a few sections:

  • Cover page and offering summary. These show the securities offered, the price per unit and the exchange listing, if any.
  • Use of proceeds. For a clinical-stage or development-focused biopharma company, this section shows how much of the money goes to research, trials and working capital. It may also show whether any goes to repaying debt.
  • Dilution. This compares the new price with net tangible book value per share. It shows how much value existing holders give up.
  • Capitalization. This shows the share count and balance-sheet position before and after the offering.
  • Underwriting. This covers discounts, any overallotment option, and lock-up terms that limit insider selling.
  • Risk factors. Biopharma filings usually include going-concern language, regulatory risk and dependence on clinical results where they apply.

Who is affected

The people most affected are the investors who bought in the offering. Existing shareholders are also affected, because new securities change their ownership percentage. Trading volume and price behavior in the first sessions after pricing will show how the market receives the terms. That is the subject of first-day performance analysis.

What to watch next

Watch for closing of the offering and any follow-up filings, such as a current report on Form 8-K. Also watch for trading data after the deal. If the offering includes an overallotment option, a later filing may show whether underwriters exercised it. Floto Review will cover the pricing terms in more detail as they are verified against the full prospectus text.

Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

Related